Header

May 22nd - World Pre-Eclampsia Day

Early diagnosis of Pre-Eclampsia can save lives.

Header

International Woman's Day - 8th March 2022

International Women’s Day is a time to celebrate the social, economic, cultural and political achievements of women everywhere. This year, the focus is on how to #breakthebias

Header

Cerca Biotech

Cerca Biotech is the European subsidiary of Shuwen Biotech, who you might already recognise as being a highly reputable and innovative molecular and point of care diagnostics organisation.

Header

Mamma Typer®

it’s time to take the stage.

MammaTyper

MammaTyper® is a new tool for subtyping breast cancer.

READ MORE +
Preclampsia

A rapid, simple, Point Of Care screening test for urinary congophilia.

READ MORE +

ABOUT US

Cerca Biotech

Cerca Biotech is the European subsidiary of Shuwen Biotech, a highly reputable and innovative molecular and point of care diagnostics organisation. Shuwen and Cerca are passionate about healthcare and are working to create world-leading innovations in the fields of Oncology and Women’s Health.

About
Discover

MammaTyper® - It’s time to take the stage

Innovation for your breast cancer diagnostics

High-performance test

Quantitative RT-qPCR assay (CE marked IVD)

  • Highly reproducible biomarker assessment
  • Reliable results through standardized biomarker detection
  • Accurate stratification of breast cancer tumors into St Gallen subtypes

Promising clinical utility

Clinical value validated in numerous performance evaluation studies

  • Outperforms IHC by accurate Ki-67 determination
  • Provides information on patient‘s prognosis
  • Accurate subtyping supports treatment decisions

Easy-to-use

Clinical value validated in numerous performance evaluation studies

  • Reliable method for any molecular pathology laboratory
  • Validated for multiple qPCR instruments*
  • From resection or core needle biopsy FFPE sample to result within 6 hours FFPE = formalin fixed paraffin embedded
Discover

Pre-Eclampisia Vue™

For a safe pregnancy

NEWS

Recent article and news

11 Jul 2022

Ki-67; Love it or Hate it?

Ki-67 is a great aid in the diagnosis and treatment of a variety of cancers. If you are a patient looking for more information, you might find this article a bit technical, but you can still head on over to cercabiotech.com for our patient-focussed information which we hope can help.

19 May 2022

World Pre Eclampsia Day (May 22nd)

Early diagnosis of Pre-Eclampsia can save lives. Yet, definitive detection of this potentially fatal condition can be delayed or difficult to access under current testing regimes. To help combat this issue, Cerca Biotech is launching a new, rapid point-of-care test designed for use in maternity departments and primary care settings. 

31 Mar 2022

MammaTyper® announces registration in Italy

We are really pleased to announce that MammaTyper® has been registered by the Ministero della Salute in Italy. This marks a key step towards bringing this innovative, RT-qPCR test to the Italian market and helping women who have been diagnosed with breast cancer. This announcement follows our earlier news that Padua-based firm AB Analytica will be the exclusive distributor for MammaTyper® in Italy.